Rhythm Pharmaceuticals Inc (RYTM) Inventory Turnover Ratio, from third quarter 2026 to third quarter 2025, current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 
Rhythm Pharmaceuticals Inc   (NASDAQ: RYTM)
 

Rhythm Pharmaceuticals Inc Inventory Turnover Ratio (COS)

Cost of Sales Formula, Quarterly Results, Trends, Rankings, Statistics

Rhythm Pharmaceuticals Inc inventory turnover ratio, the Rhythm Pharmaceuticals Inc 's ability to sell and replace its inventory in the third quarter 2026, sequentially increased to 1.14 in the third quarter 2026, RYTM's markets remain strong, its supply chain continue to be in a grate shape.Average inventory processing period, for the Rhythm Pharmaceuticals Inc in Sep 30 2026 quarter, has decreased to 320 days, compare to 369 days, in the Jun 30 2026 quarter.

Within Healthcare sector 299 other companies have achieved higher inventory turnover ratio. While in terms of ranking among all other companies, the company has moved form 660 in the second quarter 2026, to 1817.

RYTM Inventory Turnover Ratio using Sales Formula
What is Inventory Turnover Ratio?
What is Rhythm Pharmaceuticals Inc Market Share?

What is Inventory Turnover Ratio?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

RYTM Inventory Turnover Ratio (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Inventory Growth 41.07 % 61.71 % 48.33 % 37.42 % 59.1 %
Y / Y Cost of Sales Growth 121.24 % 61.12 % 96.19 % 26.84 % 43.65 %
Inventory Turnover Ratio (TTM) 1.14 0.99 0.96 0.91 0.94
RYTM's Total Ranking # 1817 # 660 # 1381 # 1155 #
Average inventory processing period 321 370 378 403 390
Seq. Inventory Growth 2.2 % 6.51 % 11.25 % 16.49 % 17.14 %
Seq. Cost of Sales Growth 36.22 % 24.79 % 49.04 % -12.68 % -0.79 %




Inventory Turnover Ratio Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 85
Healthcare Sector # 300
Overall Market # 1817

Inventory Turnover Ratio Statistics
High Average Low
1.38 1.09 0.89
(Mar 31 2024)   (Mar 31 2025)



RYTM Company Profile >> Back to RYTM Efficiency Comparisons >> Compare RYTM Inventory Turnover Ratio to its Competitors

Financial Statements
Rhythm Pharmaceuticals Inc 's Inventories $ 31 Millions Visit RYTM's Balance sheet
Rhythm Pharmaceuticals Inc 's Cost of Revenues TTM $ 33 Millions Visit RYTM's Income Statement
What are RYTM's Sales? Visit RYTM's Sales by Segment

Other Inventory Turnover Ratios
Rhythm Pharmaceuticals Inc 's Inventory to Sales Ratio
U.S. Durable Goods Inventory to Shipment Ratio By Product
Major Pharmaceutical Preparations Industry Inventory Turnover Trends and Statistics
Healthcare Sector Inventory Turnover Statistics
Inventory Turnover Trends for overall market
RYTM's Inventory Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Inventory Turnover
Lowest Ranking Inventory Turnover
Inventory Turnover for RYTM's Competitors
Inventory Turnover Ratio for RYTM's Suppliers
Inventory Turnover Ratio for RYTM's Customers

You may also want to know
RYTM's Sales Growth Rates RYTM's Pe Price to earnings ratio RYTM's Receivables Turnover Ratio RYTM's Stock Quote
RYTM's Net Income Growth Rates RYTM's Ps Price to Sales ratio RYTM's Sales per Employee RYTM's Asset Turnover Ratio
RYTM's Net Margin RYTM's Pb Price to Book ratio RYTM's Financial Strength Ratios RYTM's Dividend Payout Ratio



Companies with similar Inventory Turnover Ratio for the quarter ending Sep 30 2026, within Healthcare Sector Inventory Turnover Ratio Cost of revenues at quarter ending Sep 30 2026 Inventories at quarter ending Sep 30 2026
Zai Lab Limited  2.91 $ 200.083  Millions$ 69  Millions
Amneal Pharmaceuticals Inc   2.90 $ 1,910.255  Millions$ 658  Millions
Neogen Corporation  2.89 $ 464.774  Millions$ 161  Millions
Ani Pharmaceuticals Inc  2.87 $ 405.540  Millions$ 142  Millions
Zevra Therapeutics Inc   2.82 $ 6.736  Millions$ 2  Millions
Biomerica Inc   2.65 $ 4.297  Millions$ 2  Millions
Dexcom Inc   2.65 $ 1,867.500  Millions$ 705  Millions
Dentsply Sirona Inc   2.65 $ 1,769.000  Millions$ 668  Millions
Avita Medical Inc   2.58 $ 14.936  Millions$ 6  Millions
Angiodynamics Inc   2.50 $ 142.709  Millions$ 57  Millions
Abeona Therapeutics Inc   2.46 $ 13.630  Millions$ 6  Millions
Pro dex Inc   2.45 $ 53.753  Millions$ 22  Millions
Illumina Inc   2.36 $ 1,458.000  Millions$ 618  Millions
Tela Bio Inc   2.35 $ 26.999  Millions$ 11  Millions
Mirum Pharmaceuticals Inc   2.35 $ 59.684  Millions$ 25  Millions
Aquestive Therapeutics Inc   2.34 $ 16.928  Millions$ 7  Millions
Lifevantage Corp  2.33 $ 39.482  Millions$ 17  Millions
Resmed Inc   2.33 $ 2,214.675  Millions$ 952  Millions
Beta Bionics Inc   2.31 $ 53.285  Millions$ 23  Millions
Merit Medical Systems Inc  2.25 $ 817.001  Millions$ 363  Millions
Rigel Pharmaceuticals Inc  2.24 $ 29.869  Millions$ 13  Millions
Bioventus Inc   2.24 $ 183.856  Millions$ 82  Millions
Johnson and Johnson  2.17 $ 32,222.000  Millions$ 14,824  Millions
Orasure Technologies Inc  2.17 $ 66.055  Millions$ 30  Millions
Standard Biotools Inc   2.16 $ 39.539  Millions$ 18  Millions
Adc Therapeutics Sa  2.14 $ 5.857  Millions$ 3  Millions
Icu Medical Inc  2.14 $ 1,304.538  Millions$ 609  Millions
Glaukos Corp  2.13 $ 131.180  Millions$ 62  Millions
Halozyme Therapeutics Inc   2.13 $ 319.654  Millions$ 150  Millions
Organon and Co   2.08 $ 2,859.000  Millions$ 1,371  Millions

Date modified: 2026-11-04T15:25:17+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.